Ultrasensitive diagnostics using RNA fragmentomics
| Reference number | |
| Coordinator | Göteborgs universitet - Göteborgs universitet Inst f biomedicin |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - January 2026 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Important results from the project
The aim of the project was to conduct Europe´s first RNA fragmentomics study to evaluate this new method in the field of cancer to determine if it was possible to identify treatment-indicative biomarkers. Our project goals have been achieved by developing an experimental platform for RNA fragmentomics for clinical cancer diagnostics and with data analysis models to support personalized treatment decisions. We have successfully conducted a pilot study with blood samples from sarcoma patients.
Expected long term effects
Our results show that RNA fragmentomics is a valuable research tool and has potential in molecular diagnostics. Today, a small number of RNA biomarkers are used in the clinic. We expect that their use will increase significantly in the coming years, especially in the field of precision medicine. Here, RNA fragmentomics will have an important place, as the analysis is agnostic and can in principle be applied to all clinical and biological sample types.
Approach and implementation
The project has been carried out by researchers from Gothenburg University, MultiD Analyses and RealSeq Biosciences, where scientific and commercial work packages have been completed. RealSeq has contributed the RNA fragmentomics technology and reagents, Gothenburg University has carried out the planned pilot study based on the analysis of blood samples collected from sarcoma patients and MultiD has developed the data analysis pipeline with analysis methods implemented in their software.